Compare NCRA & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NCRA | RNAZ |
|---|---|---|
| Founded | 2002 | 2016 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1M | 3.6M |
| IPO Year | 2022 | 2021 |
| Metric | NCRA | RNAZ |
|---|---|---|
| Price | $1.89 | $2.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 305.3K | 29.8K |
| Earning Date | 04-15-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $13,627,944.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.06 | $2.24 |
| 52 Week High | $3.98 | $20.99 |
| Indicator | NCRA | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 50.15 | 27.14 |
| Support Level | $0.18 | N/A |
| Resistance Level | $2.59 | $6.15 |
| Average True Range (ATR) | 0.19 | 0.36 |
| MACD | -0.09 | -0.02 |
| Stochastic Oscillator | 14.12 | 2.01 |
Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.